🏗️ This follows a previous €45 million investment, totaling over €80 million.
📏 The expansion adds 62,000 square meters, doubling the site’s footprint to 108,000 square meters.
🚀 Their goal is to enhance capabilities and maintain innovation in high-potent active pharmaceutical ingredient (HPAPI) processing.
Introduction:
The article discusses Axplora’s significant investment plans aimed at expanding its Farmabios site in Gropello Cairoli, Italy. This strategic expansion is designed to enhance the company’s capabilities in the production of highly potent active pharmaceutical ingredients (HPAPIs) and to provide a robust infrastructure for its partners and innovation initiatives.
- Axplora has committed €35 million ($40.2 million) for the expansion of its Farmabios facility, bringing its total investment to over €80 million ($93.7 million).
- The expansion will add 62,000 square meters (667,000 square feet) to the existing facility, resulting in a total area of 108,000 square meters (1,162,500 square feet).
- This investment is part of an ongoing growth trajectory for Farmabios, which has seen the development of new micronization and storage capabilities over the past five years.
- The facility is designed to safely handle high potency APIs, meeting strict Occupational Exposure Limit (OEL) standards and incorporating advanced containment measures.
- Farmabios is also equipped with specialized facilities for cytotoxic and sterile processing, alongside comprehensive research and development and supply chain capabilities.
Conclusion:
Axplora’s expansion of its Farmabios site represents a significant investment in the biopharmaceutical sector, reflecting the company’s commitment to innovation and safety in the production of APIs. This move is expected to enhance their operational capabilities while positioning Farmabios as a leader in the high-potency ingredient market, ultimately benefitting their partnerships and enhancing product offerings in the future.
